Eureka!

Greg Meyers, Executive Vice President and Chief Digital & Technology Officer at Bristol Myers Squibb (BMS) discusses how technology can be leveraged to drive outcomes.See www.mckinsey.com/privacy-policy for privacy information

Lykke Hinsch Gylvin shares how Boehringer Ingelheim’s innovative clinical trial designs bring therapies to patients faster.See www.mckinsey.com/privacy-policy for privacy information

John Marioni discusses how he and his teams across industries and academia use evolving technologies to bring sophisticated drug therapies to patients.See www.mckinsey.com/privacy-policy for privacy information

In this episode of Eureka!, a McKinsey podcast on innovation in life sciences R&D, hosts Navraj Nagra, Alex Devereson, and Meredith Langstaff speak to Ashita Batavia, head of hematology and oncology data sciences, R&D, at Johnson & Johnson Innovative Medicine (J&J). They discuss how real-world data can better inform clinical trials, the shifts in mindsets and capabilities needed to support AI in biopharma, and how to navigate the complexity of clinical trials with more-pragmatic trial designs.See www.mckinsey.com/privacy-policy for privacy information

In this episode, hosts Navraj Nagra and Alex Devereson speak to Kim Branson, senior vice president and global head of AI and machine learning at GSK. They discuss how these emerging technologies are being used to potentially reshape how drugs are developed and about the complexities AI and machine learning introduce in data management, cross-functional collaboration, and responsible innovation.See www.mckinsey.com/privacy-policy for privacy information

In this episode, Howard Jacob, AbbVie’s vice president of genomics research and head of data integration, discusses early adoption of data integration at AbbVie, the challenges of medical silos, and the steps needed to build novel AI and machine learning capabilities with McKinsey’s Alex Devereson, Erika Stanzl, and Navraj Nagra. Together, explore how AI and genomics can better define diseases and discuss the importance of building trust in new technologies through patient-centric initiatives.See www.mckinsey.com/privacy-policy for privacy information

Marcus Schindler, chief scientific officer, and head of research and early development at Novo Nordisk, shares the ways in which he's leading the company’s efforts to embrace external innovation and expand into new therapeutic areas with AI as a powerful catalyst for progress with McKinsey colleagues Alex Devereson and Nav Nagra. Learn more about the McKinsey R&D practice here.See www.mckinsey.com/privacy-policy for privacy information